Hypoglycemia, Hyperglycemia, and Gatifloxacin
- Weerapan Khovidhunkit, MD, PhD; and
- Sarat Sunthornyothin, MD
- From Chulalongkorn University, Bangkok, Thailand 10330.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: Gatifloxacin is being widely used to treat a variety of infections. Recently, concerns have been raised about the effect of gatifloxacin on glucose metabolism (1-3).
Objective: To describe cases of …
This 100-word excerpt has been provided in the absence of an abstract.
Most Read
